NASDAQ:BCTX
BriaCell Therapeutics Corp. Stock News
$1.69
+0.1000 (+6.29%)
At Close: May 31, 2024
BriaCell 2023 SABCS Posters Confirm Activation of Cancer-Fighting Immune Cells and Identify Potential Predictors of Clinical Benefit
09:00am, Wednesday, 06'th Dec 2023
PHILADELPHIA and VANCOUVER, British Columbia, Dec. 06, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell Records New Responder with Remarkable Improvement of “Eye-Bulging” Metastatic Tumor
07:00am, Thursday, 30'th Nov 2023
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 30, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
PHILADELPHIA and VANCOUVER, British Columbia, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biotechnolog
BriaCell Forms Medical Advisory Board of Distinguished Breast Cancer Specialists to Advance its Lead Oncology Candidate
09:15am, Wednesday, 25'th Oct 2023
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 25, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
October is Breast Cancer Awareness Month – BriaCell is Leading the Fight with its Innovative Technology
09:15am, Friday, 20'th Oct 2023
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 20, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell Announces Presentations at the 2023 Society for the Immunotherapy of Cancer (SITC) and San Antonio Breast Cancer (SABC) Conferences
09:00am, Wednesday, 18'th Oct 2023
PHILADELPHIA and VANCOUVER, British Columbia, Oct. 18, 2023 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio
BriaCell Therapeutics: Fast-Tracking High-Potential Breast Cancer Immunotherapy
08:02am, Monday, 30'th Jan 2023
BriaCell Therapeutics aims to create cancer immunotherapy by irradiating and engineering existing cancer cells. Lead candidate Bria-IMT for breast cancer showed good tolerability and efficacy in 46 he
BriaCell to Present New Clinical Data at the 2022 San Antonio Breast Cancer Symposium® December 6th and 7th
09:15am, Wednesday, 28'th Sep 2022
PHILADELPHIA and VANCOUVER, British Columbia, Sept. 28, 2022 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bi
Why Is BriaCell (BCTX) Stock Moving Today?
10:34am, Wednesday, 13'th Apr 2022
BriaCell Therapeutics (BCTX) stock is on the move Wednesday morning after getting Fast Track approval from the FDA for Bria-IMT. The post Why Is BriaCell (BCTX) Stock Moving Today?
Why BriaCell Therapeutics Stock Is Surging Today
09:28am, Wednesday, 13'th Apr 2022
BriaCell Therapeutics Corp (NASDAQ: BCTX) shares are trading higher Wednesday after the company announced the U.S. Food and Drug Administration granted Fast Track status to Bria-IMT for the treatm
BCTX stock unchanged after updates on buyback program (NASDAQ:BCTX)
02:34pm, Thursday, 10'th Feb 2022 Seeking Alpha
BriaCell Therapeutics (BCTX) announced on Thursday that the company was selected to perform a presentation on off-the-shelf cancer therapies at the American Association for Cancer
Active Stocks Momentum: BriaCell Therapeutics Corp. (NASDAQ:BCTX), DigitalBridge Group, Inc. (NYSE:DBRG)
11:55pm, Thursday, 16'th Dec 2021 Stock Equity
BriaCell Therapeutics Corp. (NASDAQ:BCTX) with the stream of 3.88% also noticed, India DigitalBridge Group, Inc. (NYSE:DBRG) encountered a rapid change of -1.36% in the last hour of Thursdays trading session. The post Active Stocks Momentum: BriaCell Therapeutics Corp. (NASDAQ:BCTX), DigitalBridge Group, Inc. (NYSE:DBRG) appeared first on Stocks Equity .
Big Trade Sends Briacell Therapeutics Stock Higher
02:41pm, Thursday, 16'th Dec 2021 Schaeffers Investment Research
An investor agreed to buy 1.59 million shares, or 10% of its basic common shares
BriaCell Announces Insiders Intention to Purchase up to 10% of Public Market Securities
01:00pm, Thursday, 16'th Dec 2021 Intrado Digital Media
NEW YORK and VANCOUVER, British Columbia, Dec. 16, 2021 (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXW) (TSX-V:BCT) (BriaCell or the Company) , a clinical-stage biotechnology company specializing in targeted immunotherapies for advanced breast cancer and other cancers, announces that certain members of its Board of Directors and Management team (the Insiders) have informed the Company of their intention, on an individual basis and not in concert, to use their personal funds to purchase approximately 10% of the Companys basic common shares outstanding.
Big Trade Sends Briacell Therapeutics Stock Higher
09:41am, Thursday, 16'th Dec 2021
The shares of Briacell Therapeutics Corp (NASDAQ:BTCX) are up 6.8% at $8.53 this morning, following the company's announcement that an insider intends to acquire up to 1.59 million shares, which repre
